148 related articles for article (PubMed ID: 7237450)
1. Improved antitumor activity of basic amino acid and dipeptide derivatives of daunorubicin on EL4 leukemia cells in mice.
Sela BA; Levin Y
Cancer Treat Rep; 1981; 65(3-4):277-81. PubMed ID: 7237450
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of selected daunorubicin derivatives in mice with P 388 leukemia.
Kuśnierczyk H; Rak J; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1986; 34(3):259-62. PubMed ID: 3592929
[TBL] [Abstract][Full Text] [Related]
3. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
Giuliani F; Casazza AM; Di Marco A; Savi G
Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
[TBL] [Abstract][Full Text] [Related]
4. [Nitroxyl derivatives of rubomycin].
Emanuél' NM; Konovalova NP; D'iachkovskaia RF; Denisova LK
Antibiotiki; 1982 Nov; 27(11):811-5. PubMed ID: 7181462
[TBL] [Abstract][Full Text] [Related]
5. In vivo cytotoxicity and antineoplastic activity of a transferrin-daunorubicin conjugate.
Lemieux P; Pagé M; Noël C
In Vivo; 1992; 6(6):621-7. PubMed ID: 1296812
[TBL] [Abstract][Full Text] [Related]
6. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors.
Broggini M; Italia C; Colombo T; Marmonti L; Donelli MG
Cancer Treat Rep; 1984 May; 68(5):739-47. PubMed ID: 6586294
[TBL] [Abstract][Full Text] [Related]
7. 4-Demethoxy-4-alkoxydaunorubicins.
Bernardi L; Masi P; Sapini O; Suarato A; Arcamone F
Farmaco Sci; 1979 Oct; 34(10):884-9. PubMed ID: 510530
[TBL] [Abstract][Full Text] [Related]
8. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug.
Szabó I; Manea M; Orbán E; Csámpai A; Bosze S; Szabó R; Tejeda M; Gaál D; Kapuvári B; Przybylski M; Hudecz F; Mezo G
Bioconjug Chem; 2009 Apr; 20(4):656-65. PubMed ID: 19296605
[TBL] [Abstract][Full Text] [Related]
9. Levodopa and dopamine analogs: dihydroxy and trihydroxybenzylamines as novel quinol antitumor agents in experimental leukemia in vivo.
Wick MM
Cancer Treat Rep; 1981; 65(9-10):861-7. PubMed ID: 7273019
[TBL] [Abstract][Full Text] [Related]
10. [Synthesis of rubomycin 13-tert-butoxycarbonylhydrazone and the study of its antitumor action].
Povarov LS; Gol'dberg LE; Bazhanov VS; Olsuf'eva EN; Averbukh LA
Antibiotiki; 1981 Nov; 26(11):813-6. PubMed ID: 6895688
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
13. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
[TBL] [Abstract][Full Text] [Related]
14. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
15. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.
Schwartz HS; Grindey GB
Cancer Res; 1973 Aug; 33(8):1837-44. PubMed ID: 4720795
[No Abstract] [Full Text] [Related]
16. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
Fang L; Zhang G; Li C; Zheng X; Zhu L; Xiao JJ; Szakacs G; Nadas J; Chan KK; Wang PG; Sun D
J Med Chem; 2006 Feb; 49(3):932-41. PubMed ID: 16451059
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic activity of 2-chloroethylnitrosocarbamoyl derivatives of amino acids in a transplanted rat leukemia (L 5222).
Zeller WJ; Berger M; Eisenbrand G; Tang W; Schmähl D
Arzneimittelforschung; 1982; 32(5):484-6. PubMed ID: 7201823
[TBL] [Abstract][Full Text] [Related]
18. New N-amino acid derivatives of daunorubicin.
Dzieduszycka M; Stefanska B; Borowski E; Martelli S
Farmaco Sci; 1986 Nov; 41(11):881-91. PubMed ID: 3803566
[TBL] [Abstract][Full Text] [Related]
19. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
[TBL] [Abstract][Full Text] [Related]
20. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
